Detailed guidance AEs reporting in clinical trials ( CT-3 ) Stefano Bonato, M.D. Pharmacovigilance Country Head Bayer HealthCare Pharmaceuticals
|
|
- Chrystal Kelley
- 8 years ago
- Views:
Transcription
1 Detailed guidance AEs reporting in clinical trials ( CT-3 ) Stefano Bonato, M.D. Pharmacovigilance Country Head Bayer HealthCare Pharmaceuticals
2 Pharmacovigilance costs 0.12%-0.22% of hospital admissions result in death due to an ADR corresponding to 100, ,000 deaths annually in the EU 3-10 % of hospital admissions are caused by ADRs corresponding to millions annually in the EU % of hospitalised patients suffer an ADR, corresponding to million annually in the EU ADR-related costs other than those caused by hospitalization are estimated at 63.2 billion annually in the EU 79 billion represents a reasonable estimate of the total societal cost of ADRs occurring in the EU (Source: European Commission SEC (2008) 2670)
3 Aims December 2008: Proposal of three measures by the EU Commission for safe, innovative and accessible medicines for patients: 1. Modernise Pharmacovigilance to improve the safety of medicines 2. Improve patient safety by reducing the infiltration of counterfeit medicines into the supply chain 3. Improve patient access to high quality information on health and prescription-only medicines available
4 New EU PV Legislation Directive 2010/84/EU (amending Directive 2001/83/EC) implementation by 21 JUL 2012 EU Regulation 1235/2010 (amending EU Regulation 726/2004) implementation by 02 JUL 2012 Good Pharmacovigilance Practices (GVP) (will replace Volume 9a) GVP will consist of 16 modules, implementation JUL DEC 2012 A seismic shift in EU regulatory approach with major impact on industry Transition times will mean a shifting environment until 2015
5 Some changes to come (1) Definition of Adverse Event / Adverse Reaction DDPS > PV system master file (PSMF) Consumer reports > reportable Non-serious EU PM reports > reportable (90 days) Public access to EudraVigilance DB Centralisation of ICSR and PSUR submission > simplified reporting (~ 2015)
6 Some changes to come (2) PSUR: new concept, risk based frequency Measuring effectiveness of Risk minimization activities Post Authorization Efficacy Studies (PAES vs. PASS) Conditional authorisations and additional monitoring: black symbol Transparency: PSUR AR, RMP summaries > public
7 First-wave GVP modules 7 draft modules, publication of final documents June/July 2012: Module I: Module II: Module V: Module VI: Module VII: Module VIII: Module IX: PV Systems and their Quality Systems PV System Master File Risk Management Systems Data Management of ICSRs PSURs PASSs Detection and Management of Signals and information
8 Second-wave GVP modules 9 modules (drafts expected Q3), final documents expected: December 2012 Module III: Module IV: Module X: Module XI: Module XII: Module XIII: Module XIV: Module XV: Module NR: Pharmacovigilance Inspections Audits Post-Authorisation Efficacy Studies Public Participation in Pharmacovigilance Continuous PV, Ongoing Benefit-Risk Evaluation, Regulatory Action and Planning of Public Communication Incident Management Educational and Communication Tools and Materials for Pharmacovigilance and Risk Minimisation Effectiveness of Risk Minimisation Referral Procedures for Safety Reasons
9 CT-3 (Official Journal of the EU - June 11, 2011) Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use replaces: Revision 2 of the Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use (April 2006) Detailed guidance on the European database of Suspected Unexpected Serious Adverse Reactions (Eudravigilance Clinical Trial Module) Questions & Answers specific to adverse reaction reporting in clinical trials
10 CT-3 (Official Journal of the EU - June 11, 2011) It strengthens: Eudravigilance Clinical Trial Module (EVCTM) which will become the unique tool to collect all SUSARs reported by sponsors [Such strengthening isn t complete yet so detailed guidelines are described on transitory as well as ultimate measures]
11
12 Implications Strategic implications Resource implications Workload / staff IT solutions PASS & PAES Product information (additional monitoring / black symbol) Transparency Legal implications
13 New EU PV Legislation - summary Rationalize & strengthen the PV systems > proactive PV Simplified regulatory decision making Increased involvement of patients Increased transparency Additional activities require human and financial resources
14 Current trends > proactive PV More reporting More focus on benefit-risk More transparency
15 Thank you!
The information contained in these slides is for general purposes only and presents the state of knowledge at November 30, 2011
1 The information contained in these slides is for general purposes only and presents the state of knowledge at November 30, 2011 No rights can be derived from this information The Medicines Evaluation
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/541760/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/541760/2011 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration with Member
More informationAgence fédérale des médicaments et des produits de santé
Agence fédérale des médicaments et des produits de santé From Risk Management Plan to Risk Minimization Activities New Royal Decree: Status and General Explanation Role of the Pharmacovigilance Department
More informationQuestions & answers on signal management
23 October 2015 EMA/261758/2013 Inspections and Human Medicines Pharmacovigilance Division This document addresses a number of questions which stakeholders, in particular marketing authorisation holders
More informationGuideline on good pharmacovigilance practices (GVP)
9 April 2013 EMA/816573/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file (Rev 1) Draft of first version finalised by the Agency in collaboration
More informationClinical trials: from European perspective to National implementation. CTFG / FAMHP / pharma.be. Brussels, 19 November 2010
Clinical trials: from European perspective to National implementation CTFG / FAMHP / pharma.be Brussels, 19 November 2010 Safety in clinical trials: From detection to decision How safety events are captured
More informationICRIN Seminar on EU Regulation of Clinical Trials
ICRIN Seminar on EU Regulation of Clinical Trials 12 th March 2013, Dublin J. Michael Morris Director Scientific Affairs IRISH MEDICINES BOARD 28/03/2013 Slide 1 Overview Clinical Trial (CT) legislation
More informationOne-year report on human medicines pharmacovigilance tasks of the European Medicines Agency
8 April 2014 EMA/171322/2014 Pharmacovigilance Department One-year report on human medicines pharmacovigilance tasks of the European Medicines Agency Reporting period: 2 July 2012 to 1 July 2013 7 Westferry
More informationEudraVigilance stakeholder change management plan
26 October 2015 EMA/797114/2014 Information Management Division Consultation of Project Maintenance Group 1 15 July 2015 Consultation of Eudravigilance Expert Working Group 23 September 2015 Consultation
More informationEUROPEAN MEDICINES PRACTICES AND TOOLS AGENCY DRUG SAFETY
EUROPEAN MEDICINES AGENCY DRUG SAFETY PRACTICES AND TOOLS Henry Fitt, Kevin Blake, Xavier Kurz Pharmacovigilance & Risk Management European Medicines Agency, London Contents Eudravigilance & Signal Detection
More informationCompetentes en Medicamentos
VIII Encuentro de Autoridades Competentes en Medicamentos de los Países Iberoamericanos (EAMI) 12-14 de Mayo 2010 Madrid MARTIN TERBERGER Jefe de la Unidad de Productos Farmacéuticos Nuevas iniciativas
More informationGood practice guide on recording, coding, reporting and assessment of medication errors
1 2 3 14 April 2015 EMA/762563/2014 Pharmacovigilance Risk Assessment Committee (PRAC) 4 5 6 Good practice guide on recording, coding, reporting and assessment of medication errors Draft Draft finalised
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/876333/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions Draft finalised by the Agency in collaboration with Member States 7 February 2012 Definitions
More informationComparison of EU-Pharmacovigilance System Master File (PSMF) with US System
Comparison of EU-Pharmacovigilance System Master File (PSMF) with US System Wissenschaftliche Prüfungsarbeit Zur Eralngung des Titels Master of Drug Regulatory Affairs der Mathematisch-Naturwissenschaftlichen
More informationPost-authorisation safety studies and the EU PAS Register
Post-authorisation safety studies and the EU PAS Register Xavier Kurz European Medicines Agency EMA, 11 October 2012 An agency of the European Union Content of the presentation 1. PASS: definition and
More informationReport to the European Commission on Pharmacovigilance audits carried out in the Medicines Evaluation Board, The Netherlands period of time from
Report to the European Commission on Pharmacovigilance audits carried out in the Medicines Evaluation Board, The Netherlands period of time from September 2013 to September 2015 1. INTRODUCTION Applicable
More informationPharmacovigilance System Master File (PSMF), QPPV and audits
Federal Agency for Medicines and Health Products (FAMHP) Pharmacovigilance System Master File (PSMF), QPPV and audits Matthijs Nele, PhV Inspector, DG Inspection BRAS - FAMHP/NM/ 1 Content Introduction
More informationElectronic exchanges of individual case safety reports (ICSRs) with ANSM (National Agency of Medicine and Health Product safety)
Pharmacovigilance information for pharmaceutical companies Electronic exchanges of individual case safety reports (ICSRs) with ANSM (National Agency of Medicine and Health Product safety) This document
More informationGuidance notes on collection of drug safety information by employees and agents of pharmaceutical companies
Guidance notes on collection of drug safety information by employees and agents of pharmaceutical companies March 2013 Guidance notes on collection of drug safety information by employees and agents of
More informationEMA pharmacovigilance system manual
30 June 2014 EMA/623550/2013 Inspections and Human Medicines Pharmacovigilance Division Version 1.1 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile
More informationThe New EU Clinical Trial Regulation Potential Impacts on Sites
The New EU Clinical Trial Regulation Potential Impacts on Sites Angela Papa Associate Director, Clinical Management PPD Pierre-Frédéric Omnes Director, Site Start-Up and Regulatory INC Research Faculty
More informationImplementation strategy for ISO IDMP in EU
Implementation strategy for ISO IDMP in EU Paolo Alcini Head of Data Standardisation and Analytics Business Data & Analytics Information Management EMA An agency of the European Union The EU ISO IDMP Task
More informationEphMRA Adverse Event Reporting Guidelines 2013
EphMRA Adverse Event Reporting Guidelines 2013 Based upon the Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products European
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/827661/2011 Guideline on good pharmacovigilance practices (GVP) Module IX Signal management Draft finalised by the Agency in collaboration with Member States and submitted to ERMS FG 19
More informationGood practice guide on recording, coding, reporting and assessment of medication errors
23 October 2015 EMA/762563/2014 Pharmacovigilance Risk Assessment Committee (PRAC) Good practice guide on recording, coding, reporting and assessment of medication errors Final Draft finalised by Project
More informationGuidance notes. for Patient Safety and Pharmacovigilance in Patient Support Programmes
Guidance notes for Patient Safety and Pharmacovigilance in Patient Support Programmes 9 May 2011 Approval Status Authors The ABPI Pharmacovigilance Expert Network Change History N/A Approval Date 9 May
More informationEphMRA Adverse Event Reporting Guidelines 2015
EphMRA Adverse Event Reporting Guidelines 2015 Based upon the Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products European
More informationRisk Management Plan for Drug Establishments
Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION Risk Management Plan for Drug Establishments Center for Drug Regulation and Research Food and Drug Administration 17 December
More informationSerious Breaches. Ian Gravenor. Senior Clinical Project Manager Novo Nordisk Ltd
Serious Breaches Ian Gravenor Senior Clinical Project Manager Novo Nordisk Ltd Serious Breaches of GCP or the Trial Protocol Agenda Why report? The legislation MHRA Guidance document Timelines Actions
More informationGuideline on good pharmacovigilance practices (GVP)
19 April 2013 EMA/813938/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies (Rev 1) Draft of first version finalised by the Agency in collaboration
More informationGuidance notes on the management of adverse events and product complaints from digital media
Guidance notes on the management of adverse events and product complaints from digital media Guidance notes on the management of adverse events and product complaints from digital media ABPI Pharmacovigilance
More informationStakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes
Stakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes Dr Anya Sookoo, Expert Inspector, Inspections, Enforcement & Standards Division,
More informationQuality in pharmacovigilance systems
Quality in pharmacovigilance systems June 20 th, 2014 Lisa Stagi, Medical Compliance Leader Roche Spa Quality systems in pharmacovigilance: legal requirements Regulation 1235/2010 e Directive 2010/84 Legal
More informationPHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING
PHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING This guideline supersedes guideline PHV 4 as of September 16 2008. 1. Introduction and general provisions 1.1 Purpose of the guideline The guideline
More informationEU Individual Case Safety Report (ICSR) 1 Implementation Guide
4 December 2014 EMA/51938/2013 EU Individual Case Safety Report (ICSR) 1 Implementation Guide Start of Public Consultation 30 April 2014 End of Public Consultation 30 June 2014 Final draft agreed by Project
More informationSchneps, Leila; Colmez, Coralie. Math on Trial : How Numbers Get Used and Abused in the Courtroom. New York, NY, USA: Basic Books, 2013. p i.
New York, NY, USA: Basic Books, 2013. p i. http://site.ebrary.com/lib/mcgill/doc?id=10665296&ppg=2 New York, NY, USA: Basic Books, 2013. p ii. http://site.ebrary.com/lib/mcgill/doc?id=10665296&ppg=3 New
More informationBEST PRACTICE GUIDE for Handling of Periodic Safety Update Reports
EMEA/CMDv/408477/2007 12 March 2009 BEST PRACTICE GUIDE for Handling of Periodic Safety Update Reports Edition number : 00 Edition date: 12 March 2009 Implementation date : 27 March 2009 CMD(v) Secretariat:
More informationStandard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL
Page 1 of 10 Standard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL SOP ID Number: Effective Date:01/08/2012 Version Number & Date of Authorisation: V02,
More informationMedDRA in pharmacovigilance industry perspective
MedDRA in pharmacovigilance industry SFDA ICH MedDRA Workshop, Beijing, 13 14 May 2011 Christina Winter, MD, FFPM Medical director GlaxoSmithKline R&D / ICH MedDRA Management Board 2011 ICH International
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT
More informationRisk Management Plan (RMP) Guidance (Draft)
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour
More informationQuestions and Answers to the Annual Safety Report
Questions and Answers to the Annual Safety Report Frequently asked questions regarding the Development Safety Update Report (DSUR) Question 1 DSUR Start Stop 1.1 When to start preparing and where to submit
More informationEU Clinical Trials Regulation Regulation EU 536/2014
EU Clinical Trials Regulation Regulation EU 536/2014 María Jesús Zafra Director, QA & Compliance Table of contents 1 2 3 4 Introduction Timelines and main changes Highlights 5 Impact on company processes
More information20 & 21 October 2005 Clinical trials Risk issues within a wider Europe. Adrien Collovray Marsh Life Science Conference 2005 Berlin, Germany
20 & 21 October 2005 Clinical trials Risk issues within a wider Europe Adrien Collovray Life Science Conference 2005 Berlin, Germany Clinical trials EC Directive on clinical trials Insurance Requirements
More informationThe EMA current activities towards ISO IDMP implementation
The EMA current activities towards ISO IDMP implementation An overview Ginas meeting 11 June 2014 Presented by: Ilaria Del Seppia, B-BD-DCM EMA An agency of the European Union Outlines EMA Vision: Objectives
More informationClinical research: where are we with the new (Paediatric) RC trial Regulation
where are we with the new (Paediatric) RC trial Regulation, MD, PhD Ethical Committee DEEP Former member of the PDCO EMA With the aid of Fabio D'Atri European commission and Anabela Marcal of EMA The new
More informationMonitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency
28 August 2015 EMA/386784/2015 Inspections and Human Medicines Pharmacovigilance Division Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the
More informationRisk management plans an overview
Risk management plans an overview Elspeth Kay Director, Risk Management Plan Evaluation Section, Post-marketing Surveillance Branch, Monitoring and Compliance Division, TGA ARCS-TGA workshop 12 March 2015
More informationextended EudraVigilance Medicinal Product Dictionary (XEVMPD) Data-Entry Tool (EVWEB) user manual
extended EudraVigilance Medicinal Product Dictionary (XEVMPD) Data-Entry Tool Version 5.2 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20
More informationBiotech Concerto #3. European Clinical Trial Environment
Biotech Concerto #3 European Clinical Trial Environment December 2008 Index EU Directive EU Approval System European Authority: EMEA The Guidance Documents Route Map Challenges EMEA Organization Chart
More informationSeminario SSFA. New Guideline on Good Pharmacovigilance Practice (GVP) Fare clic per modificare lo stile del sottotitolo dello schema
Seminario SSFA New Guideline on Good Pharmacovigilance Practice (GVP) Pharmacovigilance Systems and their Quality Systems Milano, 20th April 2012 GIULIA M. VALSECCHI The proposed GVP - Module 1 Guidance
More informationOverview of Risk Management
Overview of Risk Management Risk Management Plans- An Industry Perspective Dr. Sudhichai Chokekijchai, CSO Novartis (Thailand) Limited (adapted from an RMP training by Dr Judith Sills, Global Head, Medical
More informationEU PAS Register Guide
29 March 2016 EMA/613603/2012 (currently ENCePP E-Register of Studies) The EU PAS Register is temporarily hosted on the ENCePP website www.encepp.eu 1. Introduction... 2 2. ENCePP E-Register as a temporary
More informationThe Impact and Use of Social Media in Pharmacovigilance
The Impact and Use of Social Media in Pharmacovigilance Unlocking Social Media s Value Into Your Company s Strategy Pharmacovigilance practice has evolved and grown more complex over the past 5 to 10 years
More informationGuideline on good pharmacovigilance practices (GVP)
15 April 2014 EMA/876333/2011 Rev 3* Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions (Rev 3) Date for coming into effect of first version 2 July 2012 Date for coming into effect
More informationClinical Research in Mauritius
BOARD OF INVESTMENT Clinical Research in Mauritius This document provides an informative summary of the procedure to apply for a clinical research protocol in Mauritius. Contents INTRODUCTION... 2 I. APPLICATION
More informationThe European regulatory system for medicines and the European Medicines Agency
The European regulatory system for medicines and the European Medicines Agency A consistent approach to medicines regulation across the European Union An agency of the European Union This booklet is intended
More informationMedDRA in clinical trials industry perspective
MedDRA in clinical trials industry SFDA ICH MedDRA Workshop, Beijing, 13 14 May 2011 Christina Winter, MD, FFPM Medical director GlaxoSmithKline R&D / ICH MedDRA Management Board 2011 ICH International
More informationRisk Management Plan - Bayer Experience :
Risk Management Plan - Bayer Experience : Organization & Processes Najoua ADYEL Pharmacovigilance Country Head Maghreb Introduction: Pharmacovigilance toward maturity 50 s and 60 s: from nothing to reacting
More informationCOMMISSION STAFF WORKING DOCUMENT EXECUTIVE SUMMARY OF THE IMPACT ASSESSMENT. Accompanying the document
EUROPEAN COMMISSION Brussels, 26.6.2013 SWD(2013) 235 final COMMISSION STAFF WORKING DOCUMENT EXECUTIVE SUMMARY OF THE IMPACT ASSESSMENT Accompanying the document Proposal for a Regulation of the European
More informationGuideline on Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs)
London, 21 April 2009 Doc. Ref. EMA/13432/2009 Committee for Medicinal Products for Human Use (CHMP) Guideline on Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports
More informationThe European System for Monitoring Drug Safety, EudraVigilance
Paper RC07 The European System for Monitoring Drug Safety, EudraVigilance (Version 1.0) Hans-Georg Wagner, European Medicines Agency, London, UK Olivier Simoen, European Medicines Agency, London, UK Timothy
More informationEU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
More informationST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/873138/2011 (superseded version) Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products Draft finalised by the
More informationCLINICAL RESEARCH IN EUROPE AFTER THE EU DIRECTIVE ON CLINICAL TRIALS. DOMENICO CRISCUOLO, MD, FFPM CMO at CREABILIS THERAPEUTICS IFAPP PAST PRESIDENT
CLINICAL RESEARCH IN EUROPE AFTER THE EU DIRECTIVE ON CLINICAL TRIALS DOMENICO CRISCUOLO, MD, FFPM CMO at CREABILIS THERAPEUTICS IFAPP PAST PRESIDENT EU : SOME FACTS 25 MEMBERS + 3 CANDIDATES 500.000.000
More informationWhite Paper The EU Clinical Trials Regulation Main Changes and Challenges
White Paper The EU Clinical Trials Regulation Main Changes and Challenges Table of Contents 1. Introduction... 3 2. Main Changes and Associated Challenges... 4 2.1 Procedure for Initial Authorisation...
More informationPatient Support Programs and Market Research Programs in Pharmacies: Managing Safety Information
Patient Support Programs and Market Research Programs in Pharmacies: Managing Safety Information Suzete Costa Pharm D, MPH Executive Director of the Centre for Health Evaluation & Research (CEFAR) National
More informationREGULATORY REQUIREMENTS OF PHARMACOVIGILANCE SYSTEM AND ITS COMPARISON IN INDIA AND USA
ISSN: 2230-7346 Krupa C. Thula et al. / JGTPS / 6(1)-(2015) 2351 2356 (Review Article) Journal of Global Trends in Pharmaceutical Sciences Journal home page: www.jgtps.com REGULATORY REQUIREMENTS OF PHARMACOVIGILANCE
More informationEuropean Regulatory Newsletter July - September 2013
European Regulatory Newsletter July - September 2013 Introduction CROMSOURCE is committed to sharing our expertise with our clients and future clients. This reflects the first part of our Advise Agree
More informationOfficial Journal of the European Union. (Acts whose publication is obligatory)
27.12.2006 L 378/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 12 December 2006 on medicinal products for paediatric use and amending
More informationRisk Management in the Pharmaceutical Industry. Elena Apetri, Global Medical Safety Surveillance Schering AG
Risk Management in the Pharmaceutical Industry Elena Apetri, Global Medical Safety Surveillance Schering AG Topics Environment Safety Risk Management Guidance Safety RM Systems Signal detection and evaluation
More informationThe Clinical Trials Regulation EU No 536/2014: and Phase I trials
The Clinical Trials Regulation EU No 536/2014: and Phase I trials EUFEMED, Brussels, 20 May 2015 Presented by Fergus Sweeney Head, Inspections and Human Medicines Pharmacovigilance An agency of the European
More informationYOUR GATEWAY TO. EXPERIENCE, quality & FLEXIBILITy
YOUR GATEWAY TO EXPERIENCE, quality & FLEXIBILITy DATA MANAGEMENT SERVICES The quality of your data defi ne the success of your trial, therefore proper handling of data is fundamental. Our Data Management
More informationRisk Management Plan (RMP) on Biologicals and NCE
Transformation towards a New Regulatory Paradigm Risk Management Plan (RMP) on Biologicals and NCE Junko SATO International Coordination Officer PMDA, Japan 1 2 Pharmaceuticals and Medical Devices Agency
More informationWissenschaftliche Prüfungsarbeit. zur Erlangung des Titels. Master of Drug Regulatory Affairs
TITLE PAGE The new Clinical Trial Regulation and corresponding new EU portal and database: an opportunity to enhance standardisation and interoperability in regulatory systems Wissenschaftliche Prüfungsarbeit
More informationPreparation of a Meaningful and Appropriate Risk Management Plan a Multifunctional Task. Wissenschaftliche Prüfungsarbeit. zur Erlangung des Titels
Preparation of a Meaningful and Appropriate Risk Management Plan a Multifunctional Task Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels Master of Drug Regulatory Affairs der Mathematisch-Naturwissenschaftlichen
More informationGuide to Clinical Trial Applications
Guide to Clinical Trial Applications AUT-G0001-9 DATE 29 JUNE 2015 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS
More informationThe Trans-Tasman Early Warning System. Processes in Australia and New Zealand
The Trans-Tasman Early Warning System Processes in Australia and New Zealand Version 1.0 May 2013 About Medsafe Medsafe is the New Zealand Medicines and Medical Devices Safety Authority and is responsible
More informationEUDRAVIGILANCE TELEMATICS IMPLEMENTATION GROUP
European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use London, 29 October 2004 Doc. Ref: EMEA/115735/2004 EUDRAVIGILANCE TELEMATICS IMPLEMENTATION GROUP NOTE FOR GUIDANCE ON
More informationGuidance for the format and content of the protocol of non-interventional post-authorisation safety studies
26 September 2012 EMA/623947/2012 Patient Health Protection Guidance for the format and content of the protocol of non-interventional post-authorisation Introduction From 10 January 2013, marketing authorisation
More informationLevonorgestrel/Ethinylestradiol 150/30 Microgram Coated Tablets PL 20117/0044
Levonorgestrel/Ethinylestradiol 150/30 Microgram Coated Tablets PL 20117/0044 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product
More informationMedicines and Healthcare products Regulatory Agency
Medicines and Healthcare products Regulatory Agency 11 April 2016 Update on progress with the Joint Patient Safety and Vigilance Strategy Purpose: This paper provides the Board with an update on the Joint
More informationPHARMACOVIGILANCE IN A BOX
PHARMACOVIGILANCE IN A BOX Evolution of Pharmacovigilance Over the years the role of Pharmacovigilance or Product Vigilance (PV) has changed from capturing and reporting adverse events to a business imperative
More informationStandard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s. Lisa Austin, Research Manager
Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s Author: Lisa Austin, Research Manager Purpose and Objective: To identify and standardise
More informationISSUING THE AIR OPERATOR CERTIFICATE, OPERATIONS SPECIFICATIONS, AND COMPLETING THE CERTIFICATION REPORT
ISSUING THE AIR OPERATOR CERTIFICATE, OPERATIONS SPECIFICATIONS, AND COMPLETING THE CERTIFICATION REPORT GUIDANCE MATERIAL FOR INSPECTORS CA AOC-017 AIR OPERATOR CERTIFICATION RECORD OF AMENDMENTS Amendment
More informationHow To Understand The Paediatric Regulation
Paediatric Use Marketing Authorisation (PUMA) from a National Competent Authority Point of View DGRA Annual Congress 2006 Bonn, 10. May 2006 Dr. Susanne Keitel Content PUMA The Future Background Legislative
More informationThe Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner. May 2010
The Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner May 2010 Background (1) The Clinical Trials Directive 2001/20/EC The intention of this Directive
More informationRAPID ALERT SYSTEM (RAS) IN PHARMACOVIGILANCE
3BC6a RAPID ALERT SYSTEM (RAS) IN PHARMACOVIGILANCE Guideline Title Rapid Alert System (RAS) in Pharmacovigilance Legislative basis Directive 65/65/EEC as amended, Council Regulation 2309/93 Date of first
More informationA 4.5 Validity Period of a Marketing Authorisation
104 A 4.5 Examples of situations in which the notification procedure according to Art. 61(3) of the Community Code will apply are as follows: Minor changes to the package leaflet resulting from readability
More informationMedical Information and Pharmacovigilance through acquisition. Lisa Hughes Medical Affairs Manager Actavis UK Ltd
Medical Information and Pharmacovigilance through acquisition Lisa Hughes Medical Affairs Manager Actavis UK Ltd Disclaimer The views and opinions expressed in the following presentation are those of the
More informationEMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART
EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,
More informationSTANDARD OPERATING PROCEDURE FOR RESEARCH. 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol
Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol
More informationGuideline on good pharmacovigilance practices (GVP)
8 September 2014 EMA/873138/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products (Rev 1) Date for coming into effect
More informationThe EU Clinical Trial Regulation A regulator s perspective
5 The EU Clinical Trial A regulator s perspective Author Martyn Ward, Group Manager, Licensing, Medicines and Healthcare products Regulatory Agency (MHRA), UK. Keywords Clinical Trial Directive (the Directive);
More informationData submission of authorised medicines in the European Union
23 February 2015 EMA/471367/2014, Rev. 1 1 Business Data and Support Department Data submission of authorised medicines in the European Union Outlines on Article 57(2) of Regulation (EC) No 726/2004 1
More informationElectronic Payment Schemes Guidelines
BANK OF TANZANIA Electronic Payment Schemes Guidelines Bank of Tanzania May 2007 Bank of Tanzania- Electronic Payment Schemes and Products Guidleness page 1 Bank of Tanzania, 10 Mirambo Street, Dar es
More informationQuestions and answers on preparation, management and assessment of periodic safety update reports (PSURs)
18 April 2013 EMA/CVMP/PhVWP/126661/2009-Rev.3 Committee for Medicinal Products for Veterinary Use Questions and answers on preparation, management and assessment of Output from the training of veterinary
More informationMemantine hydrochloride 20 mg film-coated tablets PL 17907/0291
Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 13 Summary of Product Characteristics
More information